2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH

US11713304B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• The Broad Institute, Inc. · US
• President and Fellows of Harvard College · US
• The General Hospital Corporation · US

Inventors

• Stefan Nikolaus Gradl · Berlin, DE
• Duy Nguyen · Berlin, DE
• Knut Eis · Berlin, DE
• Judith Günther · Berlin, DE
• Timo Stellfeld · Berlin, DE
• Andreas Janzer · Berlin, DE
• Sven Christian · Berlin, DE
• Thomas Müller · Bonn, DE
• Sherif El Sheikh · Neheim, DE
• David B. Sykes · Cambridge, US
• Steven James Ferrara · Cambridge, US
• Michael Kröber · Berlin, DE
• Claudia Merz · Berlin, DE
• Michael Niehues · Berlin, DE
• Martina SCHÄFER · Berlin, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Carl Friedrich Nising · Leverkusen, DE

Key dates

• Filing date: Aug 20, 2021
• Grant date: Aug 1, 2023
• Expiry date: Aug 20, 2041

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and prophylaxis of diseases, in particular hyperproliferative disorders, as a sole agent or in combination with other active ingredients.